NCT02523690

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

Evaluating Lorcaserin Drug Therapy For ICU-Acquired Weakness: A Pilot Randomized Trial

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

ICU acquired muscle weakness is a significant problem in patients recovering from critical illness. This trial will evaluate the safety and efficacy of a drug in improving muscle weakness in critically ill patients.

Conditions

• Muscle Weakness
• Sepsis

Interventions

Type	Name	Description
DRUG	Lorcaserin	10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
DRUG	Placebo	Oral or enteral, single dose. Oral or enteral, single dose two days later

Timeline

• Start date: 2015-12-01
• Primary completion: 2017-12-01
• Completion: 2017-12-01
• First posted: 2015-08-14
• Last updated: 2020-01-13
• Results posted: 2020-01-13

Locations

1 site across 1 country: United States